A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors

TitleA prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors
Publication TypeJournal Article
Year of Publication1999
AuthorsLeBlanc R, Roy J, Demers C, Vu L, Cantin G
JournalBone Marrow Transplant
Pagination991 - 6
Date PublishedMay
ISSN0268-3369 (Print) 0268-3369 (Linking)
Accession Number10373063
Keywords*Tissue Donors, Adult, Blood Coagulation Disorders / chemically induced, Cohort Studies, Factor VIII / metabolism, Female, Filgrastim / administration & dosage / *adverse effects, Hematopoietic Stem Cell Mobilization / *adverse effects, Hematopoietic Stem Cell Transplantation, Hemostasis / *drug effects, Humans, Male, Middle Aged, Platelet Aggregation / drug effects, Prospective Studies, Thrombin / biosynthesis, Transplantation, Homologous, von Willebrand Factor / metabolism

Granulocyte colony-stimulating factor (G-CSF) is used in healthy donors of peripheral blood stem cells (PBSC) for allogeneic transplantation. However, some data have recently suggested that G-CSF may induce a hypercoagulable state, prompting us to study prospectively 22 PBSC donors before and after G-CSF 5 microg/kg twice daily. We sought evidence for changes in the following parameters: platelet count, von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), beta-thromboglobulin (beta-TG), platelet factor 4 (PF-4), platelet activation markers (GMP-140 and PAC-1), activated partial thromboplastin time (aPTT), prothrombin time (PT), coagulant factor VIII (FVIII:C), thrombin-antithrombin complex (TAT), prothrombin fragment 1+2 (F1+2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) prior to G-CSF and immediately before leukapheresis. ADP-induced platelet aggregation studies were also performed. G-CSF administration produced only mild discomfort. We found a significant increase in vWF:Ag (from 0.99 +/- 0.32 U/ml to 1.83 +/- 0.69 U/ml; P

Notify Library Reference ID878

Related Incidents